Acute myeloid leukemia

Results with clinical significance

The presence and pattern of gene mutations in a known or suspected hematologic neoplasm can provide critical diagnostic, prognostic, and therapeutic information for physicians. While many hematologic neoplasms show morphologic or phenotypic similarities, most harbor a distinct composition of somatic gene mutations. In addition, many myeloid neoplasms lack a clonal bone marrow cytogenetic finding at diagnosis (normal karyotype) but can be better characterized with the aid of a sufficiently comprehensive gene mutation profile.

At Mayo Clinic Laboratories, we strive to provide the highest quality molecular services available to complement your clinical practice by offering a robust menu of clinically validated testing, including:

  • Genetic testing panels, including MayoComplete Next-Generation Sequencing testing: a comprehensive, 47-gene Myeloid Neoplasms OncoHeme panel and two acute myeloid leukemia (AML)-focused subpanels.
  • A comprehensive, disease-specific menu of fluorescence in situ hybridization (FISH) panels.
  • Molecular analysis that combines reverse transcription, real-time polymerase chain reaction (RT-PCR) technology, and DNA-based fragment analysis to evaluate measurable residual disease (MRD).

Cost-savings comparison for traditional myelodysplastic syndromes (MDS) ordering:

  • Historical ordering pattern — chromosomes and MDS FISH ordered in tandem.
  • Research has shown FISH is not needed when chromosome results are successful.
  • Mayo Clinic algorithm to hold FISH and cancel when chromosome results are successful.
  • 70% reduction in unnecessary FISH testing.
  • 100 MDS patients = average savings of $49,000.

Learn more about our AML testing algorithms.

Learn more about how to order these evaluations at your institution.